Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf654 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Hayato Tanabe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan. Hauptthemen laut MEDLINE: Glucagon, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Hyperglucagonemia contributes to disturbances in glucose metabolism. Data-driven diabetes clustering reflects risk of diabetic complications better than classical classification, type 1 diabetes (T1D) vs type 2 diabetes (T2D); however, the pathophysiological features have not been clarified.
Objective
To assess the distribution of plasma glucagon levels among clustering-based diabetes subtypes.
Methods
A total of 546 Japanese participants with T1D or T2D were categorized into 5 diabetes subtypes. Plasma glucagon levels were compared across subtypes, and factors associated with hyperglucagonemia were evaluated using logistic regression analyses.
Results
Plasma glucagon levels differed significantly among diabetes subtypes. Among the 5 subtypes, plasma glucagon levels and the frequency of hyperglucagonemia were highest in the severe insulin-resistant diabetes (SIRD) subtype (45.6%). The SIRD subtype was an independent risk factor for hyperglucagonemia (adjusted odds ratio 2.17, 95% CI 1.03-4.54, P = .041), even after adjusting for other risk factors, such as body mass index, glycated hemoglobin (HbA1c), and metabolic dysfunction–associated steatotic liver disease.
Conclusion
The distribution of plasma glucagon levels differed among the clustering-based diabetes subtypes. SIRD is a subtype of diabetes with a hyperglucagonemic phenotype. Elucidating the reason for hyperglucagonemia in SIRD may help to clarify the mechanisms underlying the unfavorable clinical phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
- Department of Diabetes, Endocrinology, Metabolism, and General Internal Medicine, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
- Shimajiri Kinsermae Diabetes Care Clinic, Okinawa 901-2126, Japan.
- Department of Diabetes and Lifestyle-Related Disease Center, Tomishiro Central Hospital, Okinawa 901-0243, Japan.
- Division of Endocrinology, Diabetes, and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), University of the Ryukyus, Okinawa 901-2725, Japan.
ORCID-Profile: Hayato Tanabe, Michio Shimabukuro
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Tanabe, H., Shimajiri, Y., Shiroma, K., Higa, M., Masuzaki, H., & Shimabukuro, M. (2025). Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf654
Vancouver
Tanabe H, Shimajiri Y, Shiroma K, Higa M, Masuzaki H, Shimabukuro M. Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf654
BibTeX
@article{Tanabe2025,
author = {Tanabe, Hayato and Shimajiri, Yoshinori and Shiroma, Kaori and Higa, Moritake and Masuzaki, Hiroaki and Shimabukuro, Michio},
title = {Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf654}
}
EUVIMED